Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-68P is a **pseudogene** corresponding to an RNA gene related to the U4 small nuclear RNA family. Pseudogenes are **non-functional sequences** that resemble functional genes but do not produce active RNA or proteins. In this case, RNU4-68P shares sequence similarity to U4 small nuclear RNA, which is an essential component of the spliceosome (the cellular machinery responsible for splicing pre-mRNA). However, due to its status as a pseudogene, RNU4-68P does **not produce functional U4 snRNA** and does not play a known biological, therapeutic, or disease-associated role[4][5]. The canonical, functional version of this family is **RNU4-2** (RNA, U4 small nuclear 2), mutations in which have been associated with neurodevelopmental disorders such as ReNU syndrome, but **RNU4-68P itself has no demonstrated function or clinical significance** as a therapeutic target[1][6]. **Key points:** - RNU4-68P is not a protein nor a functional small nuclear RNA but a pseudogene (a non-functional genetic element)[3][4][5]. - There is no evidence that it is a therapeutic target, plays any role in disease, or interacts with drugs. - The presence of “pseudogene” in its name and gene resources confirms it is not a receptor, enzyme, transporter, or drug target[4][5]. - Information about actual biological functions or disease associations pertains to active genes in the U4 snRNA family (like RNU4-2), not to RNU4-68P. **RNU4-68P should not be considered a valid molecular drug target or a molecule of direct biological or therapeutic interest.**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 68, pseudogene (RNU4-68P).